Gilead Sciences, Inc., 10% Owner at Arcus Biosciences, Inc. (RCUS), bought 1,363,636 shares at $11.00 ($15.0M) on 2025-02-18, disclosed to the SEC on 2025-02-20.
Open-market purchase of $15.0M RCUS by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| Filing → |
| XLO | BUY | 2024-04-03 | $369K | — | Filing → |
| KYTX | BUY | 2024-02-13 | $20.0M | — | Filing → |
| RCUS | BUY | 2024-01-31 | $320.0M | — | Filing → |